CD3 bispecific T-cell engagers (TCEs) are engineered antibodies that bind CD3 on T cells and target tumor-associated antigens (TAAs), activating T cells to kill cancer. However, they can trigger adverse effects like Cytokine Release Syndrome (CRS) due to on-target off-tumor toxicity.

CD3 Bispecific T-Cell Engager – Mechanism of Action